Innovent’s SINTBILO® And Olverembatinib Now Listed On China’s NRDL

Innovent Biologics, Inc., a leading biopharmaceutical company, announced that the 2024 National Reimbursement Drug List (NRDL) in China will include SINTBILO® (tafolecimab injection) for the first time, along with an additional indication for olverembatinib, a BCR-ABL inhibitor. The updated NRDL will take effect on January 1, 2025.

SINTBILO® (tafolecimab injection), an anti-PCSK9 monoclonal antibody, is now listed for adult patients with primary hypercholesterolaemia, including familial and non-familial types and mixed dyslipidemia. Marking Innovent’s entry into the cardiovascular field, SINTBILO® offers flexible dosing options—150 mg every two weeks, 450 mg every four weeks, and 600 mg every six weeks.

The treatment has demonstrated the ability to lower low-density lipoprotein cholesterol (LDL-C) by nearly 70% and reduce lipoprotein [Lp(a)] by approximately 50%. As the first domestically developed PCSK9 inhibitor on the NRDL, SINTBILO® expands treatment options for cholesterol management and supports improved care for patients with hypercholesterolaemia in China.

Dr. Michael Yu, Founder, Chairman, and CEO of Innovent, said in a statement, “We are pleased with the inclusion of SINTBILO® in the NRDL, which will significantly increase the accessibility and affordability of this innovative therapy and marks a significant achievement for both Innovent and patients with hypercholesterolemia." We are also encouraged to include the new indication of olverembatinib in the NRDL, which will benefit a broader range of CML patients. 

He further added, “As a company that aims to' empower patients worldwide with affordable, high-quality biopharmaceuticals’, Innovent continues to invest in pioneering treatments across critical areas of oncology, cardiovascular and metabolic (CVM), autoimmune, and ophthalmology where there is substantial societal need. I look forward to building an inpatient-centred approach, leveraging our product strengths, and further improving drug affordability and accessibility so that high-quality drugs can benefit more patients and their families as soon as possible. We are proud to contribute to the better care of our patients.”

In addition, the NRDL has renewed Olverembatinib’s first indication and included a new indication through a simple contract process. Olverembatinib is now covered for treating adult patients with chronic-phase or accelerated-phase chronic myeloid leukaemia (CML) with the T315I mutation, as well as those with chronic-phase CML who are resistant to or intolerant of first- and second-generation tyrosine kinase inhibitors (TKIs). Olverembatinib, the first third-generation BCR-ABL inhibitor approved by China’s National Medical Products Administration (NMPA), is being jointly commercialised in China by Innovent and Ascentage Pharma.